Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

被引:32
|
作者
Patel, P. [1 ,2 ,3 ]
Gupta, P. K. C. [1 ,2 ,3 ]
White, C. M. J. [2 ,4 ]
Stanley, A. G. [4 ]
Williams, B. [5 ,6 ]
Tomaszewski, M. [2 ,3 ,4 ]
机构
[1] Univ Hosp Leicester NHS Trust, Dept Metab Med & Chem Pathol, Leicester, Leics, England
[2] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[3] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England
[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[5] UCL, Inst Cardiovasc Sci, London, England
[6] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
基金
英国医学研究理事会;
关键词
TREATMENT-RESISTANT HYPERTENSION; SYMPATHETIC DENERVATION; ADHERENCE; URINE; ELIGIBILITY; MEDICATION; TRIAL; DRUGS;
D O I
10.1038/jhh.2015.103
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n = 34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 50 条
  • [1] Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation
    P Patel
    P K C Gupta
    C M J White
    A G Stanley
    B Williams
    M Tomaszewski
    Journal of Human Hypertension, 2016, 30 : 368 - 373
  • [2] Non-adherence to antihypertensive treatment is common in patients referred for renal denervation
    Patel, P.
    White, C.
    Damani, R.
    Gupta, P.
    Madira, W.
    Stanley, A.
    Williams, B.
    Tomaszewski, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1190 - 1190
  • [3] A practical approach to assessment of non-adherence to antihypertensive treatment
    Kocianova, Eva
    Taborsky, Milos
    Vaclavik, Jan
    JOURNAL OF HYPERTENSION, 2023, 41 (09) : 1371 - 1375
  • [4] Antihypertensive treatment and compliance - Non-adherence should be addressed first
    Parienti, JJ
    BRITISH MEDICAL JOURNAL, 2001, 323 (7321): : 1129 - 1129
  • [5] Factors associated with non-adherence to antihypertensive treatment in patients with social security
    Pocohuanca-Ancco, Lucy
    Villacorta, Juan
    Hurtado-Roca, Yamilee
    REVISTA DEL CUERPO MEDICO DEL HOSPITAL NACIONAL ALMANZOR AGUINAGA ASENJO, 2021, 14 (03): : 316 - 321
  • [6] COGNITIVE FUNCTION AND NON-ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS
    Li, S. S.
    Brondolo, E.
    Dalrymple, N.
    Schupf, N.
    Kronish, I. M.
    VALUE IN HEALTH, 2014, 17 (07) : A477 - A477
  • [7] RISK FACTORS FOR ANTIHYPERTENSIVE MEDICATION NON-ADHERENCE
    Hajjar, A.
    Ray, M.
    Tang, J.
    Wan, J. Y.
    Bailey, J. E.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 164 - 164
  • [8] How to Screen for Non-Adherence to Antihypertensive Therapy
    Gupta, Pankaj
    Patel, Prashanth
    Horne, Robert
    Buchanan, Heather
    Williams, Bryan
    Tomaszewski, Maciej
    CURRENT HYPERTENSION REPORTS, 2016, 18 (12)
  • [9] How to Screen for Non-Adherence to Antihypertensive Therapy
    Pankaj Gupta
    Prashanth Patel
    Robert Horne
    Heather Buchanan
    Bryan Williams
    Maciej Tomaszewski
    Current Hypertension Reports, 2016, 18
  • [10] The Impact of Non-Adherence to Antihypertensive Drug Therapy
    Gardezi, Syed Karam Mustafa
    Aitken, William W.
    Jilani, Mohammad Hashim
    Wilinski, Jerzy
    HEALTHCARE, 2023, 11 (22)